Effect of oral nanocurcumin in patients with Behcet's disease.

Not Applicable

• Conditions: Behcet's disease.; Behcet's disease; M35.2

• Registration Number: IRCT20160422027520N12
• Lead Sponsor: Connective Tissue Diseases Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Willingness to cooperate
Age range 20 to 60 years
Diagnosis of Behcet's disease by rheumatologist

Exclusion Criteria

Use of nutritional supplements and antioxidant and alpha-lipoic acid during a month before the study
Pregnancy and lactation
History of diabetes and other chronic diseases
The history of other autoimmune diseases
Admission rate less than 70% of supplemental intake
Smoking

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The expression of miRNAs. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;Frequency of Th17 cells. Timepoint: Before and after intervention. Method of measurement: Flow cytometry.;The expression of the RoR?. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;IL-23 and IL-17 cytokine gene expression. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;The level of IL-23 and IL-17 cytokine secretion. Timepoint: Before and after intervention. Method of measurement: Elisa.;Frequency of Treg cells. Timepoint: Before and after intervention. Method of measurement: Flow cytometry.;The expression of the Foxp3. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;TGF-b and IL-10 cytokine gene expression. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;The level of TGF-b and IL-10 cytokine secretion. Timepoint: Before and after intervention. Method of measurement: Elisa.